Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Current Deferred Revenue (2024 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Current Deferred Revenue for 2 consecutive years, with $248000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Deferred Revenue changed 0.0% year-over-year to $248000.0, compared with a TTM value of $248000.0 through Sep 2025, changed 0.0%, and an annual FY2024 reading of $248000.0, changed N/A over the prior year.
  • Current Deferred Revenue was $248000.0 for Q3 2025 at Fennec Pharmaceuticals, roughly flat from $248000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $252000.0 in Q1 2024 and bottomed at $248000.0 in Q3 2024.